Displaying 281 - 300 of 2061
Commission Order Vacates ALJ Initial Decision and Dismisses Complaint in Case Against Altria and Juul
FTC Files Amicus Brief to Clarify Antitrust Standards Involving Exclusive-Dealing and Bundling Arrangements
Altria Group/JUUL Labs, In the Matter of
The Federal Trade Commission filed an administrative complaint alleging that Altria Group, Inc. and JUUL Labs, Inc. entered a series of agreements, including Altria’s acquisition of a 35% stake in JUUL, that eliminated competition in violation of federal antitrust laws. According to the complaint, this series of agreements involved Altria ceasing to compete in the U.S. market for closed-system electronic cigarettes in return for a substantial ownership interest in JUUL, by far the dominant player in that market. In an initial decision announced on Feb. 24, 2022, Chief Administrative Law Judge D. Michael Chappell dismissed the antitrust charges in the complaint.
FTC and DOJ Propose Changes to HSR Form for More Effective, Efficient Merger Review
Statement of Chair Lina M. Khan Joined by Commissioners Slaughter and Bedoya Regarding Proposed Amendments to the Premerger Notification Form and the Hart-Scott-Rodino Rules
FTC Files Amicus Brief in Bystolic Antitrust Litigation Supporting Competition in the Hypertension Drug Market
FTC Policy Director Issues Statement Commending Maine’s Repeal of Certificate of Public Advantage Law
FTC Further Expands Inquiry Into Prescription Drug Middlemen Industry Practices
FTC Staff Opposes State Legislation in North Carolina Designed to Shield UNC Health System from Antitrust Enforcement
FTC Approves Final Order Requiring Anchor Glass Container Corp. to Drop Noncompete Restrictions That It Imposed on Workers
FTC Approves Publication of Federal Register Notice on Revisions to Parts 0-4 of the Commission’s Rules of Practice
Anchor Glass
FTC, DOJ Issue Summary on Joint Pharmaceutical Merger Analysis Workshop
FTC Approves Final Order Requiring Mastercard to Stop Blocking the Use of Competing Debit Payment Networks
Statement Regarding the Termination of Boston Scientific Corporation’s Attempted Acquisition of a Majority Stake in M.I. Tech Co., Ltd.
FTC Deepens Inquiry into Prescription Drug Middlemen
Amgen Inc. and Horizon Therapeutics plc, FTC v.
Displaying 281 - 300 of 2061